# OnCo record nct07502014 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07502014/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07502014", "NCT07502014" ;
  schema:name "A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line"@en ;
  schema:description "A phase 2 trial of iparomlimab and tuvonralimab and fruquintinib in colorectal cancer, run by Huazhong University of Science and Technology, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07502014/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07502014> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "colorectal-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/rectal-cancer/>, <https://onco.cc/cancers/colon-cancer/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/iparomlimab-tuvonralimab/>, <https://onco.cc/drugs/fruquintinib/> ;
  onco:companies <https://onco.cc/companies/qilu-pharmaceutical/> .